Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- U.S. Patent Office Confirms First of Four Viread® Patents
- Review Ongoing for Remaining Three Patents FOSTER CITY, Calif. -- Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the U.S. Patent & Trademark Office PTO has completed the first of four reexamination proceedings and has confirmed the patentability of U.S. Patent No. 6,043,230, which covers a method of use for...
- Research articles 2008-05-20
- Gilead Sciences and Royalty Pharma Announce $525 Million Agreement with Emory University to Purchase Royalty Interest for Emtricitabine
- FOSTER CITY, Calif. & NEW YORK & ATLANTA -- Gilead Sciences, Inc. (Nasdaq:GILD) and Royalty Pharma today announced that the companies have entered into an agreement with Emory University providing for the purchase of the royalty interest owed to Emory for emtricitabine, also known as EmtrivaR. Under the terms of...
- Research articles 2005-07-19
- It’s Good News, Bad News for Gilead’s HIV Pill
- The good news: The FDA approved Viread, Gilead’s dwindling HIV treatment, as a therapy for hepatitis B. The drug’s sales had gone down to $613 million from a peak of $783 million as newer combination drugs -- including Gilead’s own Atripla, which includes Viread -- eroded the market for standalone...
- Blog posts 2008-08-12
Additional Resources
- TENOFOVIR DISOPROXIL FUMARATE.(Viread from Gilead Sciences approved)(Brief Article)
- TENOFOVIR DISOPROXIL FUMARATE Gilead Sciences received FDA approval for antiretroviral agent Viread tenofovir disoproxil fumarate for human immunodeficiency virus infection when taken in ... TENOFOVIR DISOPROXIL FUMARATE Gilead Sciences received FDA approval for antiretroviral agent Viread tenofovir disoproxil fumarate for human immunodeficiency virus...
- Research articles 2001-11-05
- Gilead Reduces Price of Viread in the Developing World by 37 Percent; Anti-HIV Medication Available to 68 Resource-Limited Countries Through the Gilead Access Program
- FOSTER CITY, Calif. -- Gilead Sciences (Nasdaq:GILD) today announced a significant price reduction for VireadR tenofovir disoproxil fumarate in the developing world. Gilead provides Viread, a once-a-day antiretroviral medication for HIV to be used in combination therapy, through the Gilead Access Program at a no-profit price in every country in...
- Research articles 2004-07-09
- U.S. FDA Grants Traditional Approval for Gilead's Once-Daily HIV Medications Truvada® and Viread®; 48-Week Data from Pivotal Study 934 Added to U.S. Prescribing Information for Both Products
- FOSTER CITY, Calif. -- Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the U.S. Food and Drug Administration FDA has granted traditional approval status to its once-daily antiretroviral VireadR tenofovir disoproxil fumarate and its fixed-dose product TruvadaR emtricitabine and tenofovir disoproxil fumarate, which combines the company's two antiretrovirals EmtrivaR emtricitabine and...
- Research articles 2006-03-08
- Pivotal Studies of Gilead's Viread and Emtriva Published in Special International Aids Conference Issue of Journal of the American Medical Association
- BANGKOK, Thailand -- Data from Separate Clinical Studies Compare Safety and Efficacy of Viread and Emtriva to Stavudine
- Research articles 2004-07-11
- European Commission Approves Truvada, a Once-a-Day Tablet Containing Gilead Sciences' Anti-HIV Drugs Emtriva and Viread
- FOSTER CITY, Calif. -- Gilead Sciences (Nasdaq:GILD) today announced that the European Commission has granted a Marketing Authorisation for TruvadaR emtricitabine and tenofovir disoproxil fumarate in all 25 member states of the European Union. Truvada combines the company's anti-HIV medications EmtrivaR emtricitabine and VireadR tenofovir disoproxil fumarate in one tablet,...
- Research articles 2005-02-23
- Gilead Sciences and Aspen Pharmacare Sign Letter of Intent to Establish Non-Exclusive Licensing and Distribution Agreement for Antiretrovirals Truvada and Viread in Developing World Countries
- FOSTER CITY, Calif. & JOHANNESBURG, South Africa -- Gilead Sciences, Inc. (Nasdaq:GILD) and JSE Securities Exchange listed Aspen Pharmacare APN today announced that the companies have signed a letter of intent under which they have committed to enter into a non-exclusive licensing and distribution agreement for Gilead's antiretroviral ARV products...
- Research articles 2005-04-25
- Gilead Announces 72-Week Data From Two Pivotal Phase III Studies Evaluating Viread® for the Treatment of Chronic Hepatitis B
- - Oral Presentations at EASL Following Recent CHMP Positive Opinion Support Viread as Potential New Treatment for Life-Threatening Liver Disease -
- Research articles 2008-04-24
- GlaxoSmithKline Seeks to Commercialize Viread in China for Hepatitis B
- ChinaBio Today submits: GlaxoSmithKline GSK and Gilead Sciences GILD agreed on an Asian marketing plan for their jointly owned treatment for hepatitis B, Viread® tenofovir disoproxil fumarate. GSK will have exclusive rights to commercialize the drug for hepatitis B in China. Gilead will own exclusive rights Hong Kong, Singapore,...
- External links 2009-11-25
- Gilead Q1: Company Is Recession Resistant But Not Lawsuit Resistant
- Yet another gravity-defying quarter at Gilead: Revenues were up 22 percent to $1.5 billion; net income was up 21 percent to $589 million. But same bad news lurks behind the numbers in the form of a shareholder lawsuit that was given the go-ahead by the US Supreme Court a few...
- Blog posts 2009-04-22
- Gilead Sciences gains FDA approval for Emtriva. (Life Sciences).
- GILEAD SCIENCES Inc. has received Food and Drug Administration FDA approval for Emtriva emtricitabine, an antiretroviral. Estimates for Emtriva as a co-formulated product with Gilead's first HIV drug Viread tenofovir top $1 billion, upon a pr GILEAD SCIENCES Inc. has received Food and Drug...
- Research articles 2003-07-14
- Gilead Sciences Inc. (Active Pharmaceutical Ingredient Watch).(Brief Article)
- GILEAD SCIENCES Inc. estimates its total revenues for the second quarter 2003 in the range of $236 million to $239 million, well above consensus estimates of $179 ... GILEAD SCIENCES Inc. estimates its total revenues for the second quarter 2003 in the range of...
- Research articles 2003-07-21
- Gilead Sciences: Making Biotech Balms.
- Byline:Kiplinger Washington Editors Stocks of one-product companies tend to be volatile. Gilead Sciences GILD is no exception. The company's main product is Viread, a drug used to slow the advance of HIV infections. The stock lost...
- Research articles 2004-05-06
- Full Transcript of Gilead Sciences’ 3Q05 Conference Call — Q&A (GILD)
- Earnings Call ExcerptHere’s the entire text of the Q&A from Gilead Sciences’ (ticker: GILD) Q3 2005 conference call. The prepared remarks are here. We recognize that this transcript may contain inaccuracies - if you find any, please post a comment below and we’ll incorporate your corrections. And please note:...
- Earnings calls 2005-10-27
- Gilead's anti-AIDS drug to cost $1 a day here.
- Aug. 21--NEW DELHI -- Viread, the largest selling anti-HIV/AIDS drug in the United States, will be available to patients in India at a special price equivalent of $1 a day, its manufacturer, bio-pharmaceutical major Gilead, announced Sunday. Gilead has already entered into generic licensing...
- Research articles 2006-08-21
- U.S. FDA Approves Gilead's Truvada, a One-Tablet, Once-a-Day Fixed-Dose Co-Formulation of Viread and Emtriva as Part of HIV Combination Therapy
- FOSTER CITY, Calif. -- Gilead's Third HIV Therapeutic and Fourth Antiviral Approved in Three Years; Truvada Also Available Through Gilead Access Program for Developing World
- Research articles 2004-08-02
- Gilead Sciences Announces First Quarter 2002 Financial Results; Product Revenues Include $27.2 Million in Viread Sales
- Business Editors
- Research articles 2002-04-30
- Gilead Sciences to Provide Access to Anti-HIV Therapy Viread in 68 Developing World Countries At No Profit
- Business Editors/Medical Writers
- Research articles 2002-12-17
- << Previous
- page 1 of 1
- Next >>
